Tesamorelin ���景与作用机制 — Research Overview

By Editorial Desk · published 2026-01-06 · last reviewed 2026-02-04 · News

Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-02-04. Numbers and descriptions here follow the published literature rather than marketing material.

tesamorelin 背景与作用机制

研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。

tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。

作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。

Mechanism And Pharmacodynamic Markers

Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.

Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.

Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.

Tesamorelin at a glance

Background and Receptor Mechanism

Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.

Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.

Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.

Related pages on this site

• Sustainable analysis
• Practical review
• Professional toolkit
• Seasonal archive
• Verified report
• Lightweight collection
• Standard digest
• Quality review

Storage Handling and Analytical Methods

Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.

Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.

Identity and Development Background

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.

Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.

Mechanism And Measurement Approaches

Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.

Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.

Notes from published material

Historically, terminal elimination half-lives were considered very long, 40–50 days for Hydroxychloroquine as compared to up to 60 days for Chloroquine. More recent studies suggest a shorter half-life of about 5 days. A long Hydroxychloroquine half-life is attributed to extensive tissue uptake rather than to an intrinsic inability to clear the drug. The expected delay in the attainment of steady-state concentrations (3–4 months) may be in part responsible for the slow therapeutic response observed with Hydroxychloroquine. Agents may be used in combination, however, people may experience greater side effects. Methotrexate is the most important and useful DMARD and is usually the first treatment. A combined approach with methotrexate and biologics improves ACR50, HAQ scores and RA remission rates. This benefit from the combination of methotrexate with biologics occurs both when this combination is the initial treatment and when drugs are prescribed in a sequential or step-up manner. Triple therapy consisting of methotrexate, sulfasalazine and hydroxychloroquine may also effectively control disease activity. Adverse effects should be monitored regularly with toxicity including gastrointestinal, hematologic, pulmonary, and hepatic. Side effects such as nausea, vomiting or abdominal pain can be reduced by taking folic acid. Rituximab combined with methotrexate appears to be more effective in improving symptoms compared to methotrexate alone. Rituximab works by decreasing levels of B-cells (an immune cell that is involved in inflammation).

=== Chronic toxicity === Ingestion of melamine may lead to reproductive damage, or bladder or kidney stones, which can lead to bladder cancer. A study in 1953 reported that dogs fed 3% melamine for a year had the following changes in their urine: (1) reduced specific gravity, (2) increased output, (3) melamine crystalluria, and (4) protein and occult blood. A survey commissioned by the American Association of Veterinary Laboratory Diagnosticians suggested that crystals formed in the kidneys when melamine combined with cyanuric acid, "don't dissolve easily. They go away slowly, if at all, so there is the potential for chronic toxicity."

== Sources == Bamforth, Charles; Food, Fermentation and Micro-organisms, Wiley-Blackwell, 2005, ISBN 0-632-05987-7 Bamforth, Charles; Beer: Tap into the Art and Science of Brewing, Oxford University Press, 2009 Boulton, Christopher; Encyclopaedia of Brewing, Wiley-Blackwell, 2013, ISBN 978-1-4051-6744-4 Briggs, Dennis E., et al.; Malting and Brewing Science, Aspen Publishers, 1982, ISBN 0-8342-1684-1 Ensminger, Audrey; Foods & Nutrition Encyclopedia, CRC Press, 1994, ISBN 0-8493-8980-1 Esslinger, Hans Michael; Handbook of Brewing: Processes, Technology, Markets, Wiley-VCH, 2009, ISBN 3-527-31674-4 Hornsey, Ian Spencer; Brewing, Royal Society of Chemistry, 1999, ISBN 0-85404-568-6 Hui, Yiu H.; Food Biotechnology, Wiley-IEEE, 1994, ISBN 0-471-18570-1 Hui, Yiu H., and Smith, J. Scott; Food Processing: Principles and Applications, Wiley-Blackwell, 2004, ISBN 978-0-8138-1942-6 Andrew G.H. Lea, John Raymond Piggott, John R.

=== Photocatalysis === Being smaller than the wavelengths of visible light, nanoparticles can be dispersed in transparent media without affecting its transparency at those wavelengths. This property is exploited in many applications, such as photocatalysis.

This approach falls below international standards, where adverse action is a purely objective test. By contrast in CFMEU v Clermont Coal Pty Ltd an employer was found liable for selecting a union organiser named Mr Scott for redundancy, ostensibly on the basis of "attitude", but where all supervisor's assessments of "attitude" came from Scott's role in union organising, and Scott had an objectively better work record than others scored higher.

Sources: en.wikipedia.org

Further detail

Further extending the shelf-life of stored blood up to 42 days was an anticoagulant preservative, CPDA-1, introduced in 1979, which increased the blood supply and facilitated resource-sharing among blood banks. As of 2006 about 15 million units of blood products were transfused per year in the United States. By 2013 the number had declined to about 11 million units, because of the shift towards laparoscopic surgery and other surgical advances and studies that have shown that many transfusions were unnecessary. For example, the standard of care reduced the amount of blood transfused in one case from 750 to 200 mL. In 2019, 10,852,000 RBC units, 2,243,000 platelet units, and 2,285,000 plasma units were transfused in the United States.

Charcot–Marie–Tooth disease (CMT; , shar-KOE ma-REE TOOTH), also known as hereditary motor and sensory neuropathy (HMSN), is an inherited neurological disorder that affects the peripheral nerves responsible for transmitting signals between the brain, spinal cord, and the rest of the body. It is the most common inherited neuropathy that causes sensory and motor symptoms of numbness, tingling, weakness and muscle atrophy, pain, and progressive foot deformities over time. In some cases, CMT also affects nerves controlling automatic bodily functions like sweating and balance. Symptoms typically start in the feet and legs before spreading to the hands and arms. While some individuals experience minimal symptoms, others may face significant physical limitations. There is no cure for CMT; however, treatments such as physical therapy, orthopedic devices, surgery, and medications can help manage symptoms and improve quality of life. CMT is caused by mutations in over 100 different genes, which disrupt the function of nerve cells' axons (responsible for transmitting signals) and their myelin sheaths (which insulate and accelerate signal transmission). When these components are damaged, nerve signal transmission slows down or becomes impaired, leading to problems with muscle control and sensory feedback. The condition was discovered in 1886 by doctors Jean-Martin Charcot and Pierre Marie of France and the English neurologist Howard Henry Tooth. This disease is the most commonly inherited peripheral neuropathy, affecting approximately one in 2,500 people.

The legion was probably founded by Diocletian to help defend the Danube. I Pontica: the legion was founded by Dioceltian to help defend Pontus Polemoniacus. The legion was stationed in Trapezus. Legio II II Armeniaca II Britannica: comitatensis under Magister Peditum II Flavia Constantia: comitatensis under the command of the Magister Peditum II Flavia Virtutis: comitatensis under the command of the Magister Peditum II Herculia (devoted to Hercules): levied by Diocletian, stationed in Scythia Minor II Isaura II Iulia Alpina: pseudocomitatensis under the command of the Magister Peditum, in Comes Illyricum command. It was probably founded by Crispus or Constans. Its objective was to defend Alpes Cottiae II Felix Valentis Thebaeorum: comitatensis Legio III III Diocletiana III Flavia Salutis: comitatensis unit of the Late Roman Empire under the command of the Magister Militum in the west. The Legio III Flavia Salutis was raised by either Constantius II or Diocletian and was used to guard North Africa. III Herculea: comitatensis under the command of the Comes Illyricum III Isaura III Iulia Alpina: comitatensis under the command of the Magister Peditum command in Italy Legio IV IV Italica IV Martia IV Parthica Legio V V Iovia (maybe the Jovians) V Parthica Legio VI VI Gemella VI Gallicana VI Herculia (maybe the Herculians) VI Hispana VI Parthica Legio XII XII Victrix

Potassium alum, potash alum, or potassium aluminium sulfate is a chemical compound defined as the double sulfate of potassium and aluminium, with chemical formula KAl(SO4)2. It is commonly encountered as the dodecahydrate, KAl(SO4)2·12H2O. It crystallizes in an octahedral structure in neutral solution and cubic structure in an alkali solution with space group Pa3 and lattice parameter of 12.18 Å. The compound is the most important member of the generic class of compounds called alums, and is often called simply alum. Potassium alum is commonly used in water purification, leather tanning, dyeing, fireproof textiles, and baking powder as E number E522. It also has cosmetic uses as a deodorant, as an aftershave treatment and as a styptic for minor bleeding from shaving.

Sources: en.wikipedia.org

Supporting material

=== Use of nuclear properties === A technique similar to radioisotopic labeling is radiometric dating: using the known half-life of an unstable element, one can calculate the amount of time that has elapsed since a known concentration of isotope existed. The most widely known example is radiocarbon dating used to determine the age of carbonaceous materials. Several forms of spectroscopy rely on the unique nuclear properties of specific isotopes, both radioactive and stable. For example, nuclear magnetic resonance (NMR) spectroscopy can be used only for isotopes with a nonzero nuclear spin. The most common nuclides used with NMR spectroscopy are 1H, 2D, 15N, 13C, and 31P. Mössbauer spectroscopy also relies on the nuclear transitions of specific isotopes, such as 57Fe. Radionuclides also have important uses. Nuclear power and nuclear weapons development require relatively large quantities of specific isotopes. Nuclear medicine and radiation oncology utilize radioisotopes respectively for medical diagnosis and treatment.

== Transportation == UPS operates over 119,000 delivery vehicles worldwide, ranging from bicycles to tractor-trailer trucks. In a long-running company policy to avoid advertisement or endorsement of a vehicle manufacturer, all external manufacturer emblems and badging are removed when a vehicle enters service (whenever possible). The typical lifespan of a UPS ground vehicle is 20–25 years (or more), lasting until the structural integrity is compromised. The company does not re-sell any of its ground vehicles. As such, retired vehicles are almost always stripped of reusable parts before being sent to be crushed/broken up. Prior to scrapping, UPS trucks and trailers have all company branding painted over and are assigned an ADA (Automotive Destruction Authorization) number and must be crushed under the supervision of UPS Automotive personnel, which records the vehicle's destruction. The only exception to this policy are vehicles taken off the road for internal company use; package cars (repainted white) are used for various purposes (typically at large hubs); older semi tractors sometimes see use as terminal tractors.

Tempeh is 60% water, 20% protein, 8% carbohydrates, and 11% fats (table). In a reference amount of 100 grams (3.5 oz), tempeh supplies 192 calories, and is a rich source (20% or more of the Daily Value, DV) of several B vitamins and dietary minerals, such as riboflavin (30% DV) and manganese (62% DV), respectively (table).

Sources: en.wikipedia.org

Frequently asked questions